The global Achondroplasia Treatment Market Growth Accelerated by Emerging Drugs and Approvals
Achondroplasia is a common form of dwarfism characterized by abnormal bone growth and disproportionate short stature. Achondroplasia treatment aims to improve final adult height by stimulating cartilage and bone growth. Growing research focus on developing novel therapeutics such as gene therapy, bone morphogenetic protein inhibitors and growth hormone is driving the achondroplasia treatment market. The global Achondroplasia Treatment Market size is estimated to be valued at US$ 127.8 Mn in 2023 and is expected to exhibit a CAGR of 36% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The key trend fueling market growth is the emergence of new drugs in the pipeline. Companies are focusing on gene therapy approaches and bone morphogenetic protein inhibitors to treat the underlying cause of abnormal bone growth in achondroplasia. For instance, BioMarin received the FDA approval for vosoritide in 2023, wh...